{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"7"}]}],"title":"ATA status: Transiently positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"}]}],"title":"ATA status: Persistently positive"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"}]}],"title":"nATA status: Positive"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"16"},{"groupId":"OG002","value":"17"}],"units":"Participants"}],"description":"Blood samples were collected to assess the immunogenicity of brentuximab vedotin (ATA and nATA development) using a laboratory test. ATA-positive samples were further characterized as transiently ATA positive (defined as 1 or 2 post-Baseline ATA-positive responses), persistently ATA positive (defined as more than 2 post-Baseline ATA positive responses), and nATA positive or negative.","groups":[{"description":"Brentuximab vedotin 1.4 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle, until there was evidence of disease progression or unacceptable toxicity.","id":"OG000","title":"Brentuximab Vedotin 1.4 mg/kg: Phase 1"},{"description":"Participants with r/r HL received brentuximab vedotin 1.8 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle until there was evidence of disease progression or unacceptable toxicity (Up to 16 cycles). Treatment with brentuximab vedotin beyond 16 cycles was permitted at the joint discretion of the sponsor and the investigator for those participants experiencing continued clinical benefit.","id":"OG001","title":"Brentuximab Vedotin 1.8 mg/kg: Phase 1 and 2 r/r HL Only"},{"description":"Participants with r/r systemic anaplastic large-cell lymphoma (sALCL) received brentuximab vedotin 1.8 mg/kg, 30-minute IV infusion, Day 1 of every 21-day cycle until there was evidence of disease progression or unacceptable toxicity (Up to 16 cycles). Treatment with brentuximab vedotin beyond 16 cycles was permitted at the joint discretion of the sponsor and the investigator for those participants experiencing continued clinical benefit.","id":"OG002","title":"Brentuximab Vedotin 1.8 mg/kg: Phase 1 and 2 r/r sALCL Only"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants from the Safety Population, all enrolled participants who received at least one dose of brentuximab vedotin, with data available for analysis.","reportingStatus":"POSTED","timeFrame":"Baseline up to EOT (Up to 15 months)","title":"Number of Participants With Antitherapeutic Antibodies (ATA) and Neutralizing ATA (nATA) (Phase 1 and 2)","type":"SECONDARY","unitOfMeasure":"Participants"}